1999
DOI: 10.1002/(sici)1097-0142(19990915)86:6<1044::aid-cncr21>3.3.co;2-3
|View full text |Cite
|
Sign up to set email alerts
|

Megestrol acetate therapy and secondary adrenal suppression

Abstract: MA causes secondary adrenal suppression that is thought to be due to its effect at the hypothalamic level. The authors recommend a short course of steroid replacement for patients receiving MA at times of acute illness.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
10
0

Year Published

2002
2002
2015
2015

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(11 citation statements)
references
References 0 publications
1
10
0
Order By: Relevance
“…Megestrol acetate has glucocorticoid activity, and high doses or a prolonged treatment period with megestrol acetate reduce plasma ACTH and cortisol secretion, leading to adrenal insufficiency secondary to prolonged suppression of the hypothalamic-pituitary-adrenal axis [24][25][26][27]. In both the pilot and this study, megestrol acetate treatment was significantly associated with adrenal suppression on antiemetic dexamethasone therapy.…”
Section: Discussionmentioning
confidence: 99%
“…Megestrol acetate has glucocorticoid activity, and high doses or a prolonged treatment period with megestrol acetate reduce plasma ACTH and cortisol secretion, leading to adrenal insufficiency secondary to prolonged suppression of the hypothalamic-pituitary-adrenal axis [24][25][26][27]. In both the pilot and this study, megestrol acetate treatment was significantly associated with adrenal suppression on antiemetic dexamethasone therapy.…”
Section: Discussionmentioning
confidence: 99%
“…Critically ill cancer patients with sepsis likely represent a high-risk sub-group for CIRCI given such factors as frequent and repetitive use of systemic corticosteroids, potential malignant involvement of the adrenal gland(s), irradiation-induced insult to the HPA axis [17,18], and impaired cortisol synthesis with megestrol [19,20]. Available data on the incidence of CIRCI are limited by the exclusion of patients with known [9] or advanced cancer [4] and the lack of information regarding enrollment of cancer patients [2, 3, 5-8, 10-12, 14].…”
Section: Introductionmentioning
confidence: 67%
“…MA, a synthetic orally active progesterone derivative is being used increasingly and successfully to treat anorexia and cachexia in patients with a wide range of advanced malignancies [20][21][22]. However, MA has glucocorticoid activity and can induce significant adrenal suppression at the hypothalamicpituitary level [23][24][25][26]. In cancer patients co-treated with dexamethasone and MA, the incidence of adrenal suppression was remarkable-more than half of patients were affected in our presented study.…”
Section: Discussionmentioning
confidence: 99%